Skip to main content

Table 4 Logistic regression analysis of medication odds ratios for “Early 2020” vs. “Late 2020” study cohorts. A P-value < 0.05 was considered statistically significant

From: Investigational medications in 9,638 hospitalized patients with severe COVID-19: lessons from the “fail-and-learn” strategy during the first two waves of the pandemic in 2020

 

Odds Ratio

95% Confidence Interval

P-Value

Azithromycin “Early 2020”

0.79

0.65

0.95

0.01

Azithromycin “Late 2020”

0.68

0.56

0.82

< 0.01

Corticosteroids “Early 2020”

1.28

1.03

1.59

0.02

Corticosteroids “Late 2020”

1.36

0.74

2.48

0.32

Hydroxychloroquine “Early 2020”

0.72

0.59

0.88

< 0.01

Hydroxychloroquine “Late 2020”

1.10

0.49

2.48

0.82

Remdesivir “Early 2020”

1.21

0.98

1.51

0.08

Remdesivir “Late 2020”

0.76

0.62

0.93

0.01

Tocilizumab “Early 2020”

1.49

1.17

1.90

< 0.01

Tocilizumab “Late 2020”

1.01

0.62

1.64

0.98